

10/517338

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : National Phase Entry PCT/EP03/06591
Applicant : Sven Ole WARNAAR et al
Filed : Herewith
TC/A.U. :
Examiner :

Docket No. : 2923-672
Customer No. : 6449
Confirmation No. :

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450


Sir:

In compliance with applicants duty of disclosure under 37 C.F.R. 1.56, enclosed is a copy of the International Search Report in the corresponding international application. The relevance of the references is noted in the International Search Report. We understand that the references have been forwarded by the International Bureau, and are available to the Examiner, but if the Examiner needs copies of any of the references, the Examiner is requested to advise counsel accordingly.

In the event that any fees are due with this paper, please charge our Deposit Account No. 02-2135.

Respectfully submitted,

By



Robert B. Murray
Attorney for Applicant
Registration No. 22,980
ROTHWELL, FIGG, ERNST & MANBECK
1425 K. Street, Suite 800
Washington, D.C. 20005
Telephone: (202) 783-6040

RBM/cb

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if known	
				Application Number	National Entry of PCT/EP03/06591
				Filing Date	Herewith 10/517338
				First Named Inventor	Sven Ole WARNAAR et al
				Group Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	2923-672

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Beck Joachim et al., "A Phase I/II trial with monoclonal antibody WX-G250 in combination with low dose interleukin-2 in metastatic renal cell carcinoma", PROCEEDINGS OF THE AMERICA ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 43, March 2002, pg. 910.	
		Bleumer I et al., "A phase II trial with monoclonal antibody WX-G250 in advanced renal cell carcinoma", EUROPEAN UROLOGY SUPPLEMENTS, vol. 1, no. 1, January 2002, pg. 112.	
		Liu Zhanqi et al., "Anti-renal cell carcinoma chimeric antibody G250: Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 51, no. 3, May 2002, pgs. 171-177.	
		Van Dijk J. et al., "Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts", INTERNATIONAL JOURNAL OF CANCER, vol. 56, no. 2, 1994, pgs. 262-268.	
		Varga Z et al., "A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients", FOLIA BIOLOGICA, vol. 49, no. 2, 2003, pgs. 74-77.	
		Bleumer Ivar et al., "A phase I/II trial with chimeric monoclonal antibody WX-G250 in combination with low-dose interleukin-2 for patients with metastatic renal cell carcinoma", JOURNAL OF UROLOGY, vol. 169, no. 4 Supplement, April 2003, pg. 261.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.